Donor Statin Treatment for Prevention of Severe Acute GVHD After Myeloablative Hematopoietic Cell Transplantation
Latest Information Update: 07 Apr 2022
Price :
$35 *
At a glance
- Drugs Atorvastatin (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 26 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 04 Aug 2015 Planned primary completion date changed from 1 Jan 2016 to 1 Sep 2015 as reported by ClinicalTrials.gov.
- 21 Jul 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.